TY - JOUR
T1 - Treatment approaches and outcomes in plasmacytomas
T2 - Analysis using a national dataset
AU - Goyal, Gaurav
AU - Bartley, Adam C.
AU - Funni, Shealeigh
AU - Inselman, Jonathan
AU - Shah, Nilay D.
AU - Marshall, Ariela L.
AU - Ashrani, Aneel A.
AU - Kapoor, Prashant
AU - Durani, Urshila
AU - Hashmi, Shahrukh K.
AU - Siddiqui, Mustaqeem A.
AU - Buadi, Francis K.
AU - Go, Ronald S.
AU - Kyle, Robert A.
AU - Kumar, Shaji
AU - Gonsalves, Wilson I.
N1 - Funding Information:
Funding This research was funded by the Mayo Clinic Division of Hematology funds for the Hematology and Oncology Outcomes Research (HONOR) Group. This publication was also supported by the National Cancer Institute of the National Institutes of Health under Award Number K23CA218742.
Publisher Copyright:
© 2018 Macmillan Publishers Limited, part of Springer Nature.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Solitary plasmacytomas are uncommon plasma cell disorders, which may present as a single bone lesion (P-bone) or extramedullary plasmacytoma (P-EM). There is a paucity of large studies analyzing prognostic factors and outcomes of plasmacytomas. While the treatment of choice is radiation therapy (RT), there is a lack of data evaluating optimal RT dose. In this study, we sought to answer these questions by utilizing the National Cancer Database plasmacytoma data from 2000 to 2011. A total of 5056 patients were included in the study (median age 62 years; range 52-72). To obtain a pure plasmacytoma cohort, potential multiple myeloma patients were excluded from the study (bone marrow involvement, systemic chemotherapy use). P-bone constituted 70% of the patients. The median overall survival (OS) of P-EM was significantly longer than P-bone (132 vs. 85 months), and for soft/connective tissue it was worse than remainder of P-EM (82 vs. 148 months). On multivariable analysis, factors associated with worse OS included older age (≥65), presence of P-bone, and treatment with a radiation dose <40 Gy.
AB - Solitary plasmacytomas are uncommon plasma cell disorders, which may present as a single bone lesion (P-bone) or extramedullary plasmacytoma (P-EM). There is a paucity of large studies analyzing prognostic factors and outcomes of plasmacytomas. While the treatment of choice is radiation therapy (RT), there is a lack of data evaluating optimal RT dose. In this study, we sought to answer these questions by utilizing the National Cancer Database plasmacytoma data from 2000 to 2011. A total of 5056 patients were included in the study (median age 62 years; range 52-72). To obtain a pure plasmacytoma cohort, potential multiple myeloma patients were excluded from the study (bone marrow involvement, systemic chemotherapy use). P-bone constituted 70% of the patients. The median overall survival (OS) of P-EM was significantly longer than P-bone (132 vs. 85 months), and for soft/connective tissue it was worse than remainder of P-EM (82 vs. 148 months). On multivariable analysis, factors associated with worse OS included older age (≥65), presence of P-bone, and treatment with a radiation dose <40 Gy.
UR - http://www.scopus.com/inward/record.url?scp=85045273875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045273875&partnerID=8YFLogxK
U2 - 10.1038/s41375-018-0099-8
DO - 10.1038/s41375-018-0099-8
M3 - Article
C2 - 29654264
AN - SCOPUS:85045273875
SN - 0887-6924
VL - 32
SP - 1414
EP - 1420
JO - Leukemia
JF - Leukemia
IS - 6
ER -
